Information On Asthma

The information on this site is intended for health care professionals in the United States and is not intended for the general public.

I AM A HEALTHCARE PROFESSIONAL I AM NOT A HEALTHCARE PROFESSIONAL
Prescribing Information Patient Information Return to singulair.com

References

  1. Johnston NW, Johnston SL, Norman GR, et al. The September epidemic of asthma hospitalization: school children as disease vectors. J Allergy Clin Immunol. 2006;117:552–562.
  2. Data available on request from Merck, Professional Services-DAP, WP1-27, PO Box 4, West Point, PA 19486-0004. Please specify information package 20951047(3)-SNG.
  3. Reiss TF, Chervinsky P, Dockhorn RJ, et al; for Montelukast Clinical Research Study Group. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Arch Intern Med. 1998;158:1213–1220.
  4. Busse WW, Casale TB, Dykewicz MS, et al. Efficacy of montelukast during the allergy season in patients with chronic asthma and seasonal aeroallergen sensitivity. Ann Allergy Asthma Immunol. 2006;96:60–68.
  5. Data available on request from Merck, Professional Services-DAP, WP1-27, PO Box 4, West Point, PA 19486-0004. Please specify information package 20850998(4)-SNG.
  6. Data available on request from Merck, Professional Services-DAP, WP1-27, PO Box 4, West Point, PA 19486-0004. Please specify information package 20951045(3)-SNG.
  7. Knorr B, Matz J, Bernstein JA, et al; for Pediatric Montelukast Study Group. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. JAMA. 1998;279:1181–1186.
  8. Figueroa DJ, Breyer RM, Defoe SK, et al. Expression of the cysteinyl leukotriene 1 receptor in normal human lung and peripheral blood leukocytes, Am J Respir Crit Care Med. 2001;163:226–233.
  9. Laitinen LA, Laitinen A, Haahtela T, et al. Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet. 1993;341:989–990.
  10. Lee E, Robertson T, Smith J, et al. Leukotriene receptor antagonists and synthesis inhibitors reverse survival in eosinophils of asthmatic individuals. Am J Respir Crit Care Med. 2000;161:1881–1886.
  11. Spada CS, Nieves AL, Krauss AH-P, et al. Comparison of leukotriene B4 and D4 effects on human eosinophil and neutrophil motility in vitro. J Leukoc Biol. 1994;55:183–191.
  12. Fregonese L, Silvestri M, Sabatini F, et al. Cysteinyl leukotrienes induce human eosinophil locomotion and adhesion molecule expression via a CysLT1 receptor-mediated mechanism. Clin Exp Allergy. 2002;32:745–750.
  13. Nagata M, Saito K, Tsuchiya K, et al. Leukotriene D4 upregulates eosinophil adhesion via the cysteinyl leukotriene 1 receptor. J Allergy Clin Immunol. 2002;109:676–680.
  14. Rothenberg ME. Eosinophilia. N Engl J Med. 1998;338:1592–1600.
  15. Barnes PJ. Pharmacology of airway smooth muscle. Am J Respir Crit Care Med. 1998;158:S123–S132.
  16. Busse WW, Lemanske RF Jr. Asthma. N Engl J Med. 2001;344:350–362.
  17. Silverman RA, Stevenson L, Hastings HM. Age-related seasonal patterns of emergency department visits for acute asthma in an urban environment. Ann Emerg Med. 2003;42:577–586.
  18. Hay DWP, Torphy TJ, Undem BJ. Cysteinyl leukotrienes in asthma: old mediators up to new tricks. Trends Pharmacol Sci. 1995;16:304–309

SINGULAIR is indicated for prophylaxis and chronic treatment of asthma in patients aged 12 months and older and for prevention of exercise-induced bronchoconstriction (EIB) in patients aged 15 years and older.

For prevention of EIB, a single dose of SINGULAIR should be taken at least 2 hours before exercise. An additional dose of SINGULAIR should not be taken within 24 hours of a previous dose.

Patients already taking 1 tablet daily for another indication should not take an additional dose to prevent EIB.

SELECTED SAFETY INFORMATION

  • SINGULAIR should not be used as rescue medication to treat acute asthma episodes. Patients should be advised to have appropriate rescue medication available.
  • Neuropsychiatric events have been reported in patients taking SINGULAIR. These events included agitation, aggressive behavior or hostility, anxiousness, depression, dream abnormalities, hallucinations, insomnia, irritability, restlessness, somnambulism, suicidal thinking and behavior (including suicide), and tremor. The clinical details of some postmarketing reports appear consistent with a drug-induced effect. Patients should be advised to report any neuropsychiatric events.
  • Use of SINGULAIR may not eliminate the need for inhaled or systemic corticosteroids. Patients should not decrease the dose or stop taking any other antiasthma medications unless instructed by a physician.
  • Safety and effectiveness of SINGULAIR in patients younger than 12 months with asthma have not been established.

Before prescribing SINGULAIR, please read the Prescribing Information.

See all references.

20951836(5)-02/10-SNG

For general information and other services for physicians

Merck Services Merck OnCall

SINGULAIR, Merck OnCall, and MerckServices are registered trademarks of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.